Accessibility Tools
Invert colors
Monochrome
Dark contrast
Light contrast
Low saturation
High saturation
Highlight links
Highlight headings
Screen reader
Read mode
Content scaling
100
%
Font size
100
%
Line height
100
%
Letter spacing
100
%
Skip to main content
Home
News
Issues
Latest Issue
Issue Archive
Supplements
Conference Highlights
Multimedia
Video Library
Voices From ASCO 2025
About
Subscribe
Advertise With Us
Home
News
The Latest News and Information from ImPACT federal health
READ MORE
Issues
Latest Issue
Issue Archive
Supplements
Conference Highlights
We at ImPACT know how valuable your time is, and that you can't make it to every continuing education course out there, so we've brought you the top news from all of them.
READ MORE
Multimedia
Video Library
Voices From ASCO 2025
About
Only
ImPACT
optimizes care for our nation’s heroes because we are dedicated to unifying the Patient-Aligned Care Team (PACT) to remove barriers to care.
ABOUT IMPACT
Subscribe
Stay up to date with the latest insights from leading professionals in the federal health space by subscribing to our newsletter!
SUBSCRIBE TODAY
Advertise With Us
ImPACT
welcomes advertising and sponsorship collaborations with reputable nonprofit groups and companies offering FDA-approved treatments, sanctioned clinical trials, and high-quality products and services to health care professionals treating our nation's veterans.
CONTACT SALES
Rare Disease
Latest news in rare diseases
Rare Disease
Olezarsen Approved for Familial Chylomicronemia Syndrome
FDA News
,
Rare Diseases
January 2025, Vol 2, No 1
Olezarsen (Tryngolza; Ionis) has been approved by the FDA for the treatment of familial chylomicronemia syndrome (FCS), a rare, inherited disorder characterized by severe hypertriglyceridemia.
Read More ›
